TABLE OF CONTENTS

- Acknowledgements III
- Abstract V
- Table of contents VII
- List of tables XV
- List of figures XXI
- List of abbreviations XXVII
- List of formulas XXX

Chapter I: Introduction

1.1. Introduction
   1.1.1 Pharmaceutical Analysis 1
   1.1.2 Chromatography 3
   1.1.3 Mass Spectroscopy 9

1.2. Instrumentation
   1.2.1. High performance liquid chromatography (HPLC) 11
   1.2.2. Mass Spectrometer 18
   1.2.3. Liquid Chromatography-Mass Spectrometry (LC-MS) 19

1.3. Method Development
   1.3.1. Analytical Method Development 22
   1.3.2. Bio analytical Method Development 23

1.4. Method Validation
   1.4.1. Analytical Method Validation 26
   1.4.2. Bio analytical Method Validation 37

1.5. References 47
Chapter II: Objectives of the study

2.1. General objectives

2.1.1. Objectives of development and validation of bio analytical methods

2.1.2. Objectives of Qualitative and quantitative analysis

2.1.3. Objectives of stability indicating assays

2.2. Plan of work

2.2.1. Selection of drugs

Chapter III: Riluzole hydrochloride

3.1. Literature of Riluzole hydrochloride

3.2. Profile of the drug

3.3. Authentication of drug by spectral studies

3.4. Quantitative estimation of Riluzole in human plasma by LC-ESI-MS/MS

3.4.1. Introduction

3.4.2. Experimental

3.4.3. Method development

3.4.4. Method validation

3.4.5. Results and discussion

3.4.5.1. Method development

3.4.5.2. Method validation
3.4.6. Summary 109
3.4.7. Conclusion 110

3.5. Development and validation of RP-HPLC method for the determination of Riluzole hydrochloride in bulk and tablet dosage forms

3.5.1. Introduction 111
3.5.2. Experimental 111
3.5.3. Method development 112
3.5.4. Method validation 116
3.5.5. Results and discussion
   3.5.5.1. Method development 121
   3.5.5.2. Method validation 122
3.5.6. Summary 123
3.5.7. Conclusion 124

3.6. An improved stability-indicating HPLC method for Riluzole hydrochloride in bulk and pharmaceutical dosage forms

3.5.1. Introduction 125
3.5.2. Experimental 125
3.5.3. Method development 126
3.5.4. Method validation 131
3.5.5. Results and discussion
   3.5.5.1. Method development 139
   3.5.5.2. Method validation 149
3.5.6. Summary 151
3.5.7. Conclusion 152
Chapter IV: Rimonabant hydrochloride

4.1. Literature of Rimonabant hydrochloride
4.2. Profile of the drug
4.3. Authentication of drug by spectral studies

4.4. **RP-HPLC method development and validation of Rimonabant hydrochloride in bulk and pharmaceutical dosage forms**

4.4.1. Introduction
4.4.2. Experimental
4.4.3. Method development
4.4.4. Method validation
4.4.5. Results and discussion
   4.4.5.1. Method development
   4.4.5.2. Method validation
4.4.6. Summary
4.4.7. Conclusion

4.5. **A novel validated RP-HPLC method development for the estimation of Rimonabant hydrochloride in bulk and tablet dosage forms**

4.5.1. Introduction
4.5.2. Experimental
4.5.3. Method development
4.5.4. Method validation
4.5.5. Results and discussion
4.5.5.1. Method development 198
4.5.5.2. Method validation 200
4.5.6. Summary 201
4.5.7. Conclusion 202

4.6. A Novel Stability Indicating Liquid Chromatographic Assay for the Estimation of Rimonabant Hydrochloride in Bulk and Pharmaceutical Dosage Forms

4.6.1. Introduction 203
4.6.2. Experimental 203
4.6.2. Method development 204
4.6.3. Method validation 209
4.6.4. Results and discussion
  4.6.4.1. Method development 214
  4.6.4.2. Method validation 222
4.6.5. Summary 223
4.6.6. Conclusion 224

4.7. References 225

Chapter V: Aprepitant

5.1. Literature of Aprepitant 230
5.2. Profile of the drug 235
5.3. Authentication of drug by spectral studies 238

5.4.1. Introduction 240
5.4.2. Experimental 241
5.4.3. Method development 242
5.4.4. Method validation 245
5.4.5. Results and discussion
   5.4.5.1. Method development 252
   5.4.5.2. Method validation 254
5.4.6. Summary 256
5.4.7. Conclusion 256

5.5. A Validated Stability Indicating RP-HPLC Method for the Determination of Aprepitant in Bulk and Pharmaceutical Dosage Forms

5.5.1. Introduction 257
5.5.2. Experimental 257
5.5.3. Method development 258
5.5.4. Method validation 262
5.5.5. Results and discussion
   5.5.5.1. Method development 272
   5.5.5.2. Method validation 274
5.5.6. Summary 274
5.5.7. Conclusion 275

5.6. References 277
## Chapter VI: Orlistat

6.1. Literature of Orlistat  279

6.2. Profile of the drug  282

6.3. Authentication of drug by spectral studies  286

**6.4. A new RP-HPLC method development and validation of Orlistat in bulk and pharmaceutical dosage Forms**

6.4.1. Introduction  288

6.4.2. Experimental  288

6.4.3. Method development  289

6.4.4. Method validation  292

6.4.5. Results and discussion
  
  6.4.5.1. Method development  299
  
  6.4.5.2. Method validation  300

6.4.6. Summary  301

6.4.7. Conclusion  302

6.5. References  303

## Chapter VII: Ropinirole hydrochloride

7.1. Literature of Ropinirole hydrochloride  304

7.2. Profile of the drug  307

7.3. Authentication of drug  311
7.4. RP-HPLC method development and validation of Ropinirole hydrochloride in bulk and pharmaceutical dosage forms

7.4.1. Introduction 313
7.4.2. Experimental 313
7.4.3. Method development 315
7.4.4. Method validation 317
7.4.5. Results and discussion
   7.4.5.1. Method development 325
   7.4.5.2. Method validation 327
7.4.6. Summary 328
7.4.7. Conclusion 328

7.5. References 329

Appendix: Research publications in journals 330